ADAP News and Press, Adaptimmune Therapeutics plc From 04/13/20

Penny stocks, defined as equities that trade at less than $5 a share, are rarely worth the risk. Companies with extremely low share prices tend to have weak balance sheets, an absurdly high number of outstanding shares, few institutional investors, sky-high levels of interest from short-sellers,...

March wasn't kind to any asset class because of the COVID-19 pandemic. But the month took a particularly heavy toll on risky clinical-stage biotech stocks. Shares of  Adaptimmune Therapeutics   (NASDAQ: ADAP) , Atreca (NASDAQ: BCEL) , and CRISPR Therapeutics   (NASDAQ: CRSP) ,...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Pharmaceutical stocks were initially expected to be largely immune to the COVID-19 economic downturn. Drugmakers, after all, generally produce products that are essential to daily life. However, the extreme social distancing that has become part and parcel of this unusual period has halted nume...

Adaptimmune Therapeutics plc (ADAP) Q4 2019 Earnings Conference Call February 27, 2020 8:00 AM ET Company Participants Juli Miller - Director of Investor Relations Adrian Rawcliffe - Chief Executive Officer Helen Tayton-Martin - Chief Business Officer Elliot Norry - Chief Medic...

Adaptimmune (NASDAQ: ADAP ): Q4 GAAP EPS of -$0.05 beats by $0.27 . More news on: Adaptimmune Therapeutics plc, Earnings news and commentary, Healthcare stocks news, Read more ...

- Compelling data in synovial sarcoma in the Phase 1 trial, and continued momentum in the Phase 2 SPEARHEAD-1 trial with goal to launch ADP‑A2M4 for sarcoma in 2022 - - Encouraging demonstration of the potential of SPEAR T-cell platform in four new solid tumor indications - - Co...

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results for the Full Year / Fourth Quarter 2019 and provide a business update, before the U.S. markets ...

We're less than two months into 2020, and a handful of biotech stocks have more than doubled their investors' money already. Shares of these drugmakers have gained attention for different reasons, but their shareholders and potential new investors all want to know if they can continue to impress...

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Gavin Wood as Chief Financial Officer (CFO), effective April 1, 2020. ȁ...